75 related articles for article (PubMed ID: 3385280)
21. Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.
Sood BM; Gorla GR; Garg M; Anderson PS; Fields AL; Runowicz CD; Goldberg GL; Vikram B
Cancer; 2003 Apr; 97(7):1781-8. PubMed ID: 12655536
[TBL] [Abstract][Full Text] [Related]
22. [Flow cytometry (FCM) in the assay of DNA content of normal and malignant epithelial cells of human uterine cervix and the prognostic significance of DNA content: I. Methodology].
Wu AR
Zhonghua Zhong Liu Za Zhi; 1985 Mar; 7(2):87-90. PubMed ID: 2408835
[No Abstract] [Full Text] [Related]
23. DNA flow cytometry: a predictor of a high-risk group in cervical cancer.
Anton M; Nenutil R; Rejthar A; Kopecny J; Ptackova B; Zaloudik J
Cancer Detect Prev; 1997; 21(3):242-6. PubMed ID: 9167041
[TBL] [Abstract][Full Text] [Related]
24. MR imaging in uterine cervical cancer after radiotherapy.
Egashira K; Nakamura K; Terashima H; Nakata H; Kashimura M
Radiat Med; 1992; 10(3):117-22. PubMed ID: 1509103
[TBL] [Abstract][Full Text] [Related]
25. [The relationship between DNA content in cervical carcinoma cell and the clinicopathological features].
Zhang H
Zhonghua Bing Li Xue Za Zhi; 1989 Jun; 18(2):137-9. PubMed ID: 2582553
[TBL] [Abstract][Full Text] [Related]
26. [Radiation therapy for squamous cell carcinoma of uterine cervix using high dose rate intracavitary irradiation].
Ogawa Y; Sakamoto K
Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Oct; 54(12):1155-64. PubMed ID: 9261194
[TBL] [Abstract][Full Text] [Related]
27. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract][Full Text] [Related]
28. [DNA content in cervical cancer cells].
Avtandilov GG; Kasab'ian SS; Sgibneva OV
Vopr Onkol; 1974; 20(8):14-7. PubMed ID: 4428639
[No Abstract] [Full Text] [Related]
29. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG
J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643
[TBL] [Abstract][Full Text] [Related]
30. Carcinoma of the cervical stump. The radiumhemmet series 1959-1987. Treatment and prognosis.
Hellström AC; Sigurjonson T; Pettersson F
Acta Obstet Gynecol Scand; 2001 Feb; 80(2):152-7. PubMed ID: 11167211
[TBL] [Abstract][Full Text] [Related]
31. [The changes in nuclear DNA amounts in the development and progression of uterine cervical cancer determined by cytofluorometry].
Harada K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 May; 38(5):759-68. PubMed ID: 3722955
[TBL] [Abstract][Full Text] [Related]
32. Transperineal high-dose-rate interstitial radiation therapy in the management of gynecologic malignancies.
Itami J; Hara R; Kozuka T; Yamashita H; Nakajima K; Shibata K; Abe Y; Fuse M; Ito M
Strahlenther Onkol; 2003 Nov; 179(11):737-41. PubMed ID: 14605742
[TBL] [Abstract][Full Text] [Related]
33. Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients.
Senkus E; Konefka T; Nowaczyk M; Jassem J
Acta Obstet Gynecol Scand; 2000 Sep; 79(9):765-70. PubMed ID: 10993100
[TBL] [Abstract][Full Text] [Related]
34. Flow cytometry (FCM) of early radiation response in epidermoid carcinoma of uterine cervix.
Glasová M; Siracký J; Masák L; Kysela B
Neoplasma; 1992; 39(6):353-6. PubMed ID: 1491725
[TBL] [Abstract][Full Text] [Related]
35. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
Kim YS; Kim JH; Ahn SD; Lee SW; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1522-8. PubMed ID: 19231106
[TBL] [Abstract][Full Text] [Related]
36. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma.
Ijaz T; Eifel PJ; Burke T; Oswald MJ
Gynecol Oncol; 1998 Aug; 70(2):241-6. PubMed ID: 9740698
[TBL] [Abstract][Full Text] [Related]
37. Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
Wolfson AH; Winter K; Crook W; Krishan A; Grigsby PW; Markoe AM; Morris M; Gaffney DK; Eifel PJ; Lucci JA
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):111-7. PubMed ID: 17919835
[TBL] [Abstract][Full Text] [Related]
38. The use of glycogen studies in the evaluation of treatment for carcinoma of the cervix uteri.
Das DK; Chowdury JR
Acta Cytol; 1981; 25(5):566-71. PubMed ID: 6945022
[TBL] [Abstract][Full Text] [Related]
39. [DNA content in dysplasias and early invasive forms of cervical cancer].
Chebanu FA; Kushch AA; Zelenin AV
Vopr Onkol; 1977; 23(12):64-6. PubMed ID: 602080
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of reference points by dosimetric analyses for late complications after uniform external radiotherapy and high-dose-rate brachytherapy for cervical cancer.
Chen SW; Liang JA; Yeh LS; Yang SN; Shiau AC; Lin FJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):663-71. PubMed ID: 15380604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
